Pharmaceuticals

Hepion Pharmaceuticals

Hepion Pharmaceuticals released FY2025 9 Months Earnings on November 12 (EST), with actual revenue of USD 0 and EPS of USD -2.2851

Hepion Pharmaceuticals released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -0.0406

Hepion Pharmaceuticals released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -1.0016

Hepion Pharmaceuticals released FY2025 Q2 earnings on August 14 (EST) with actual revenue of USD 0 and EPS of USD -0.092

Hepion Pharmaceuticals Annual General Meeting Elects Directors

Hepion Pharmaceuticals released FY2025 Q1 earnings on May 19, 2025 (EST) with actual revenue of USD 0 and EPS of USD -2.1524

Hepion Pharmaceuticals Delays Release of 2025 First Quarter Financial Report

Hepion Pharmaceuticals Developing Therapies for NASH and Other Chronic Liver Diseases

Hepion Pharmaceuticals Signs LOI to Commercialize Diagnostic Tests

Hepion Pharmaceuticals and New Day Diagnostics Enter into Diagnostic Testing License Agreement

Hepion Pharmaceuticals released FY2024 Q4 earnings on April 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -11.1051 (forecast USD -98.5)

Hepion Pharmaceuticals released FY2024 annual earnings on April 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -107.3479 (forecast USD -571.5)

Hepion Pharmaceuticals released FY2024 9 Months Earnings on November 14 (EST), with actual revenue of 0 USD and EPS of -98.1837 USD

Hepion Pharmaceuticals released FY2024 Q3 earnings on November 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -36.2106 USD (forecast -95 USD)

Hepion Pharmaceuticals released FY2024 Semi-Annual Earnings on August 13 (EST), with actual revenue of 0 USD and EPS of -62.3484 USD

Hepion Pharmaceuticals released FY2024 Q2 earnings on August 13 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -33.8429 USD (forecast -185.5 USD)

Hepion Pharmaceuticals Reaches Merger Agreement with Pharma Two B

Hepion Pharmaceuticals released FY2024 Q1 earnings on May 21 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -28.1301 USD (forecast -180 USD)

Hepion Pharmaceuticals Gradually Ends ASCEND-NASH Trial Activities

Hepion Pharmaceuticals released FY2023 Annual Earnings on April 16 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -616.0728 USD (forecast -549 USD)

SMX Security Matters

Treasure Gbl

Gulf Resources

Wheeler Real Estate

Dreamland

Irobot

Praxis Precision Medicines

Click Holdings/BVI

Cemtrex

DigitalBridge

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap